NEW YORK (GenomeWeb News) – T-cell-based diagnostics development firm Lophius Biosciences today announced the closing of a financing round that brought in €4 million ($5.3 million) in funding.

Lophius will use the cash infusion to launch its technologies, it said. VRD and WIC were new investors in the round. Existing investors include S-Refit, HighTech Gründerfonds, Bayern Kapital and two angel investors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.